|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
October 12, 2005"Oral drug shows early trial promise"...MS Society of UK
"It has been shown to halve relapse rates over a 12 month clinical trial"
"Novartis, makers of the drug, which is known as FTY720, also reported that patients who switched from placebo to the treatment after six months of the phase II trial saw their yearly relapse rate reduced by at least 70%. MORE - www.mssociety.org.uk |